Table 2.
Prospective studies on impact of Oncotype DX®
| Study | Year | Publication | Country | Size | Node negative | Node positive | Percentage treatment change |
|---|---|---|---|---|---|---|---|
| Pestalozzi et al65 | 2017 | BMC Cancer | Switzerland | 222 | Yes | N1 | 15% (low-risk group) 32% (non-low-risk group) |
| Loncaster et al69 | 2017 | European Journal of Surgical Oncology | UK | 201 | Yes | N1 | 63.2% (only CHT to HT) |
| Kuchel et al67 | 2016 | British Journal of Cancer | UK | 137 | Yes | N1 | 40.70% |
| Ozmen et al70 | 2016 | Cureus | Turkey | 165 | Yes | N1mic | 33% |
| Albanell et al68 | 2016 | European Journal of Cancer | France, Germany, Spain, UK | 527 | Yes | N0 | 32% |
| Leung et al71 | 2016 | Clinical Breast Cancer | Hong Kong | 146 | Yes | N1mic | 23.30% |
| Lee et al72 | 2015 | Cancer Research and Treatment | South Korea | 212 | Yes | N1mic | 54.20% |
| Gligorov et al74 | 2015 | The Oncologist | France | 95 | Yes | N1mic | 37% |
| Bargallo et al75 | 2015 | Journal of Surgical Oncology | Mexico | 96 | Yes | N1 | 32% |
| Yamauchi et al54 | 2014 | BMC Health Services Research | Japan | 90 | Yes | N1 | 37.80% |
| de Boer et al64 | 2013 | The Medical Journal of Australia | Australia | 151 | Yes | N1 | 23.80% |
| Davidson et al73 | 2013 | European Journal of Cancer | Canada | 150 | Yes | No | 30% |
| Holt et al77 | 2013 | British Journal of Cancer | UK | 142 | Yes | N1mic | 26.80% |
| Eiermann et al76 | 2013 | Annals of Oncology | Germany | 366 | Yes | N1 | 33.10% |
| Lo et al63 | 2010 | Journal of Clinical Oncology | USA | 89 | Yes | No | 31.00% |
| Oratz et al66 | 2007 | Journal of Oncology Practice | USA | 68 | Yes | No | 21% |